1. Scrip
  2. >>Conferences
  3. >>ASH

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

(Alaric DeArment/Scrip)

The latest data and expert opinions on BCMA-directed bispecific antibodies for multiple myeloma – including Johnson & Johnson’s Tecvayli (teclistamab-cqyv) and Pfizer’s Elrexfio (elranatamab-bcmm), which have US Food and Drug Administration approval, and Regeneron Pharmaceuticals’ linvoseltamab, which is pending at the FDA – are sparking discussions about how they will fit into the market relative to each other and relative to CAR-T cell therapies.

All three bispecifics were the subject of presentations at the American Society of Hematology annual meeting, which took place in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By Kevin Grogan

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 
• By Alaric DeArment

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from Therapy Areas

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.